TABLE 1.
Description of subjects
| Subject | No. of HIV-1 RNA copies at entry | ELISA | Medicationsa | Phenotype of virusb |
|---|---|---|---|---|
| AC-01 | 250,000 | Negative | ZDV/3TC/IND | R5 |
| AC-02 | 4,850,000 | Negative | ZDV/3TC/NFV | R5 |
| AC-04 | 10,000,000 | Negative | ZDV/3TC/NFV | X4 |
| AC-05 | 1,100,000 | Weak | ZDV/3TC/NFV | R5 |
| AC-06 | 8,180,000 | Negative | D4T/3TC/NFV | R5 |
| AC-10 | 40,700 | Weak | D4T/3TC/IND | R5 |
| AC-13 | 730,000 | Negative | D4T/3TC/IND | R5 |
| AC-14 | 95,000 | Positive | D4T/3TC/IND | R5 |
| AC-16 | 337,000 | Negative | ZDV/3TC/IND | R5 |
a
D4T, stavudine; 3TC, lamivudine; IND, indinavir, ZDV, zidovudine; NFV, nelfinavir.
b
R5, CCR5 coreceptor usage; X4, CXCR4 coreceptor usage.